Table 4

Effect of amiloride or placebo on mean 24 hour heart rate variability and arrhythmia indices

ParameterBaselinePlaceboAmiloridep Value*
All values are expressed as mean (SD).
*Placebo versus amiloride treatment phases.
ΔVE/24 hours, change in frequency of ventricular extrasystoles over 24 hours from baseline; HF, high frequency; LF, low frequency; NSVT, non-sustained ventricular tachycardia; n.u., normalised unit; PIIINP, procollagen type III amino terminal peptide; RMSSD, root mean square of differences of successive RR intervals; SDANN, standard deviation of five minute mean RR intervals; SDNN, standard deviation of all RR intervals.
Time domainRR interval929 (149)945 (137)947 (131)NS
MeasuresHRV index28 (9)28 (9)31 (10)NS
SDNN114 (39)115 (36)114 (35)NS
SDANN99 (32)97 (29)99 (35)NS
RMSSD26 (6)26 (5)28 (3)NS
Frequency domainLF (n.u.)50 (22)56 (21)52 (23)NS
MeasuresHF (n.u.)45 (24)38 (22)42 (25)NS
LF/HF2.9 (2.6)3.0 (2.8)2.7 (2.4)NS
24 hour arrhythmiaΔVE/24 hoursNA−14 (279)−310 (436)<0.05
AnalysisNSVT/24 hours000NS
Vascular collagen turnoverSerum PIIINP3.2 (1.0)3.3 (1.3)3.2 (0.8)NS